Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 5/2017

Open Access 01-05-2017 | Original Article

Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1

Authors: Anchana Rathinasamy, Christoph Domschke, Yingzi Ge, Hans-Henning Böhm, Steffen Dettling, David Jansen, Felix Lasitschka, Ludmila Umansky, Markus H. Gräler, Jennifer Hartmann, Christel Herold-Mende, Florian Schuetz, Philipp Beckhove

Published in: Cancer Immunology, Immunotherapy | Issue 5/2017

Login to get access

Abstract

Regulatory T cells (Treg) hamper anti-tumor T-cell responses resulting in reduced survival and failure of cancer immunotherapy. Among lymphoid organs, the bone marrow (BM) is a major site of Treg residence and recirculation. However, the process governing the emigration of Treg from BM into the circulation remains elusive. We here show that breast cancer patients harbour reduced Treg frequencies in the BM as compared to healthy individuals or the blood. This was particularly the case for tumor antigen-specific Treg which were quantified by MHCII tumor peptide loaded tetramers. We further demonstrate that decreased Treg distribution in the BM correlated with increased Treg redistribution to tumor tissue, suggesting that TCR triggering induces a translocation of Treg from the BM into tumor tissue. Sphingosine-1-phosphate receptor 1 (S1P1)—which is known to mediate exit of immune cells from lymphoid organs was selectively expressed by tumor antigen-specific BM Treg. S1P1 expression could be induced in Treg by BM-resident antigen-presenting cells (BMAPCs) in conjunction with TCR stimulation, but not by TCR stimulation or BMAPCs alone and triggered the migration of Treg but not conventional T cells (Tcon) to its ligand Sphingosine-1-phosphate (S1P). Interestingly, we detected marked S1P gradients between PB and BM in breast cancer patients but not in healthy individuals. Taken together, our data suggest a role for S1P1 in mediating the selective mobilization of tumor specific Treg from the BM of breast cancer patients and their translocation into tumor tissue.
Appendix
Available only for authorised users
Literature
1.
go back to reference Katz SC, Bamboat ZM, Maker AV et al (2013) Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 20(3):946–955CrossRefPubMed Katz SC, Bamboat ZM, Maker AV et al (2013) Regulatory T cell infiltration predicts outcome following resection of colorectal cancer liver metastases. Ann Surg Oncol 20(3):946–955CrossRefPubMed
2.
go back to reference Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949CrossRefPubMed Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10(9):942–949CrossRefPubMed
3.
go back to reference Nummer D, Suri-Payer E, Schmitz-Winnenthal H et al (2007) Role of tumor endothelium in CD4 + CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 99(15):1188–1199CrossRefPubMed Nummer D, Suri-Payer E, Schmitz-Winnenthal H et al (2007) Role of tumor endothelium in CD4 + CD25+ regulatory T cell infiltration of human pancreatic carcinoma. J Natl Cancer Inst 99(15):1188–1199CrossRefPubMed
4.
go back to reference Simpson TR, Li F, Montalvo-Ortiz W et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695–1710CrossRefPubMedPubMedCentral Simpson TR, Li F, Montalvo-Ortiz W et al (2013) Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 210(9):1695–1710CrossRefPubMedPubMedCentral
5.
go back to reference Ge Y, Domschke C, Stoiber N et al (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61(3):353–362CrossRefPubMed Ge Y, Domschke C, Stoiber N et al (2012) Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 61(3):353–362CrossRefPubMed
6.
go back to reference Dennis KL, Wang Y, Blatner NR et al (2013) Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res 73(19):5905–5913CrossRefPubMedPubMedCentral Dennis KL, Wang Y, Blatner NR et al (2013) Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res 73(19):5905–5913CrossRefPubMedPubMedCentral
7.
go back to reference deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18(11):3022–3029CrossRefPubMed deLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18(11):3022–3029CrossRefPubMed
8.
go back to reference Beckhove P, Feuerer M, Dolenc M et al (2004) Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 114(1):67–76CrossRefPubMedPubMedCentral Beckhove P, Feuerer M, Dolenc M et al (2004) Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 114(1):67–76CrossRefPubMedPubMedCentral
9.
go back to reference Feuerer M, Beckhove P, Bai L et al (2001) Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7(4):452–458CrossRefPubMed Feuerer M, Beckhove P, Bai L et al (2001) Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 7(4):452–458CrossRefPubMed
10.
go back to reference Schirrmacher V, Feuerer M, Fournier P et al (2003) T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 9(12):526–534CrossRefPubMed Schirrmacher V, Feuerer M, Fournier P et al (2003) T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity. Trends Mol Med 9(12):526–534CrossRefPubMed
11.
go back to reference Sommerfeldt N, Schutz F, Sohn C et al (2006) The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 66(16):8258–8265CrossRefPubMed Sommerfeldt N, Schutz F, Sohn C et al (2006) The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 66(16):8258–8265CrossRefPubMed
12.
go back to reference Sommerfeldt N, Beckhove P, Ge Y et al (2006) Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 66(15):7716–7723CrossRefPubMed Sommerfeldt N, Beckhove P, Ge Y et al (2006) Heparanase: a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes. Cancer Res 66(15):7716–7723CrossRefPubMed
13.
go back to reference Schmidt HH, Ge Y, Hartmann FJ et al (2013) HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology 2(6):e24962CrossRefPubMedPubMedCentral Schmidt HH, Ge Y, Hartmann FJ et al (2013) HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients. Oncoimmunology 2(6):e24962CrossRefPubMedPubMedCentral
14.
go back to reference Bates GJ, Fox SB, Han C et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373–5380CrossRefPubMed Bates GJ, Fox SB, Han C et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24(34):5373–5380CrossRefPubMed
15.
go back to reference Hammerschmidt SI, Ahrendt M, Bode U et al (2008) Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J Exp Med 205(11):2483–2490CrossRefPubMedPubMedCentral Hammerschmidt SI, Ahrendt M, Bode U et al (2008) Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J Exp Med 205(11):2483–2490CrossRefPubMedPubMedCentral
16.
go back to reference Pham TH, Okada T, Matloubian M et al (2008) S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28(1):122–133CrossRefPubMed Pham TH, Okada T, Matloubian M et al (2008) S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity 28(1):122–133CrossRefPubMed
17.
go back to reference Zou L, Barnett B, Safah H et al (2004) Bone marrow is a reservoir for CD4+ CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 64(22):8451–8455CrossRefPubMed Zou L, Barnett B, Safah H et al (2004) Bone marrow is a reservoir for CD4+ CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 64(22):8451–8455CrossRefPubMed
18.
go back to reference Rathinasamy A, Czeloth N, Pabst O et al (2010) The origin and maturity of dendritic cells determine the pattern of sphingosine 1-phosphate receptors expressed and required for efficient migration. J Immunol 185(7):4072–4081CrossRefPubMed Rathinasamy A, Czeloth N, Pabst O et al (2010) The origin and maturity of dendritic cells determine the pattern of sphingosine 1-phosphate receptors expressed and required for efficient migration. J Immunol 185(7):4072–4081CrossRefPubMed
19.
go back to reference Cyster JG, Schwab SR (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30:69–94CrossRefPubMed Cyster JG, Schwab SR (2012) Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annu Rev Immunol 30:69–94CrossRefPubMed
20.
go back to reference Matloubian M, Lo CG, Cinamon G et al (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355–360CrossRefPubMed Matloubian M, Lo CG, Cinamon G et al (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972):355–360CrossRefPubMed
21.
go back to reference Sawicka E, Dubois G, Jarai G et al (2005) The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol 175(12):7973–7980CrossRefPubMed Sawicka E, Dubois G, Jarai G et al (2005) The sphingosine 1-phosphate receptor agonist FTY720 differentially affects the sequestration of CD4+/CD25+ T-regulatory cells and enhances their functional activity. J Immunol 175(12):7973–7980CrossRefPubMed
22.
go back to reference Ishimaru N, Yamada A, Nitta T et al (2012) CCR7 with S1P1 signaling through AP-1 for migration of Foxp3+ regulatory T-cells controls autoimmune exocrinopathy. Am J Pathol 180(1):199–208CrossRefPubMed Ishimaru N, Yamada A, Nitta T et al (2012) CCR7 with S1P1 signaling through AP-1 for migration of Foxp3+ regulatory T-cells controls autoimmune exocrinopathy. Am J Pathol 180(1):199–208CrossRefPubMed
23.
go back to reference Liu G, Burns S, Huang G et al (2009) The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol 10(7):769–777CrossRefPubMedPubMedCentral Liu G, Burns S, Huang G et al (2009) The receptor S1P1 overrides regulatory T cell-mediated immune suppression through Akt-mTOR. Nat Immunol 10(7):769–777CrossRefPubMedPubMedCentral
24.
go back to reference Bonertz A, Weitz J, Pietsch DH et al (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119(11):3311–3321PubMedPubMedCentral Bonertz A, Weitz J, Pietsch DH et al (2009) Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest 119(11):3311–3321PubMedPubMedCentral
25.
go back to reference Frevert CW, Wong VA, Goodman RB et al (1998) Rapid fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods 213(1):41–52CrossRefPubMed Frevert CW, Wong VA, Goodman RB et al (1998) Rapid fluorescence-based measurement of neutrophil migration in vitro. J Immunol Methods 213(1):41–52CrossRefPubMed
27.
go back to reference Lohr J, Ratliff T, Huppertz A et al (2011) Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 17(13):4296–4308CrossRefPubMed Lohr J, Ratliff T, Huppertz A et al (2011) Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 17(13):4296–4308CrossRefPubMed
28.
go back to reference Elkord E (2009) Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation. J Immunol Methods 347(1–2):87–90CrossRefPubMed Elkord E (2009) Frequency of human T regulatory cells in peripheral blood is significantly reduced by cryopreservation. J Immunol Methods 347(1–2):87–90CrossRefPubMed
29.
go back to reference Yu N, Li X, Song W et al (2012) CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood. Inflammation 35(6):1773–1780CrossRefPubMed Yu N, Li X, Song W et al (2012) CD4(+)CD25 (+)CD127 (low/-) T cells: a more specific Treg population in human peripheral blood. Inflammation 35(6):1773–1780CrossRefPubMed
31.
go back to reference El Andaloussi A, Lesniak MS (2006) An increase in CD4 + CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8(3):234–243CrossRefPubMed El Andaloussi A, Lesniak MS (2006) An increase in CD4 + CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 8(3):234–243CrossRefPubMed
32.
go back to reference Schwab SR, Cyster JG (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8(12):1295–1301CrossRefPubMed Schwab SR, Cyster JG (2007) Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 8(12):1295–1301CrossRefPubMed
34.
go back to reference Hammad SM, Al Gadban MM, Semler AJ, Klein RL (2012) Sphingosine 1-phosphate distribution in human plasma: associations with lipid profiles. J Lipids 2012:180705CrossRefPubMedPubMedCentral Hammad SM, Al Gadban MM, Semler AJ, Klein RL (2012) Sphingosine 1-phosphate distribution in human plasma: associations with lipid profiles. J Lipids 2012:180705CrossRefPubMedPubMedCentral
35.
go back to reference Peters JH, Koenen HJ, Fasse E et al (2013) Human secondary lymphoid organs typically contain polyclonally-activated proliferating regulatory T cells. Blood 122(13):2213–2223CrossRefPubMed Peters JH, Koenen HJ, Fasse E et al (2013) Human secondary lymphoid organs typically contain polyclonally-activated proliferating regulatory T cells. Blood 122(13):2213–2223CrossRefPubMed
36.
go back to reference Zhao E, Wang L, Dai J et al (2012) Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 1(2):152–161CrossRefPubMedPubMedCentral Zhao E, Wang L, Dai J et al (2012) Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer. Oncoimmunology 1(2):152–161CrossRefPubMedPubMedCentral
38.
go back to reference Kaiser A, Donnadieu E, Abastado JP et al (2005) CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol 175(4):2349–2356CrossRefPubMed Kaiser A, Donnadieu E, Abastado JP et al (2005) CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol 175(4):2349–2356CrossRefPubMed
39.
go back to reference Sutphen R, Xu Y, Wilbanks GD et al (2004) Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13(7):1185–1191PubMed Sutphen R, Xu Y, Wilbanks GD et al (2004) Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13(7):1185–1191PubMed
40.
go back to reference Thuy AV, Reimann CM, Hemdan NY et al (2014) Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell Physiol Biochem 34(1):158–171CrossRefPubMed Thuy AV, Reimann CM, Hemdan NY et al (2014) Sphingosine 1-phosphate in blood: function, metabolism, and fate. Cell Physiol Biochem 34(1):158–171CrossRefPubMed
42.
go back to reference Maeda Y, Matsuyuki H, Shimano K et al (2007) Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 178(6):3437–3446CrossRefPubMed Maeda Y, Matsuyuki H, Shimano K et al (2007) Migration of CD4 T cells and dendritic cells toward sphingosine 1-phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the functions of murine mature dendritic cells via S1P receptor type 3. J Immunol 178(6):3437–3446CrossRefPubMed
Metadata
Title
Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1
Authors
Anchana Rathinasamy
Christoph Domschke
Yingzi Ge
Hans-Henning Böhm
Steffen Dettling
David Jansen
Felix Lasitschka
Ludmila Umansky
Markus H. Gräler
Jennifer Hartmann
Christel Herold-Mende
Florian Schuetz
Philipp Beckhove
Publication date
01-05-2017
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 5/2017
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-017-1964-4

Other articles of this Issue 5/2017

Cancer Immunology, Immunotherapy 5/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine